Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 11, 2023 08:30 ET | Source: Mustang Bio, Inc.

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

Data showed favorable safety profile, complete response rate and durability in the treatment of patients with relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma 100% of patients with...
November 02, 2023 09:28 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

WORCESTER, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
August 16, 2023 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Initial data show clinical responses from four of four indolent lymphoma patients, including complete response in follicular lymphoma patient previously treated with CD19 CAR-T cell therapy Aligns...
December 13, 2021 09:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

95% overall response rate, 65% complete response rate and favorable safety profile in patients treated with modified cell manufacturing process Data presented at the 63rd American Society of...
December 07, 2020 07:30 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Data presented at the 62nd American Society of Hematology (ASH) Annual Meetingshow extremely favorable safety profile and clinical activity 89% overall response rate and 44% complete response rate in...
November 30, 2017 01:00 ET | Source: LAM Therapeutics

LAM Therapeutics Announces Progress of its Clinical Portfolio with FDA Clearance of New Trial in Leukemia and Advancement of Clinical Trial in Lymphoma

GUILFORD, Conn., Nov. 30, 2017 (GLOBE NEWSWIRE) -- LAM Therapeutics (LAM), a 4Catalyzer company, advanced its clinical portfolio with the U.S. Food and Drug Administration (FDA) clearance of LAM’s...